Skip to main content

Dipl.-Biochem. Mehmet Gökkaya

Junior Group Leader Immune Biomarker | Scientific Leader of Flow Cytometry Core Facility
+49 821 598 6427Email meBuilding/Room: UK Augsburg, administrative building 3 / 045

Research Areas

After graduating from the University of Tübingen in Biochemistry, Mehmet Gökkaya started his PhD thesis at the Department of Environmental Medicine. There, he studied the relationship between natural pollen exposure and the local expression of inflammatory parameters. As a scientific game changer, he focused to the local immune responses in allergic patient and looked for nasal biomarker combination for the prediction of allergic symptoms. In addition to a patent pending, Mehmet receives advancement award “Allergen Immunotherapy” of the German Society for Allergology and Clinical Immunology (DGAKI). During his PhD-thesis, he was able to publish six peer-reviewed articles and two additional articles in German. After his thesis submission, he already got his first PI-Grant from the “Bayerisches Staatsministerium für Wissenschaft und Kunst” for his current research interest in COVID-19. He is looking for early immune biomarkers for optimization of COVID-19 management.

Professional Career

01/2021 - Now

Junior Group Leader Immune Biomarker Group | Scientific Leader Core Facility Flow Cytometry

09/2016 - 12/2021

PhD submitted: Chair and Institute of Environmental Medicine, Technische Universität München und Helmholtz Zentrum München/Augsburg Thesis: “From Exposure to Reaction: Expression of immune parameters under natural pollen exposure and their effect on al

09/2008 - 01/2015

Studies and Degree of Biochemistry (Dipl. Biochem.) at Eberhard Karl Universtity of Tübingen Thesis: “ Expression of the cysteine protease cathepsin W during differentiation of human hematopoietic stem cells.”


See all

2023 Journal of Clinical Virology

Prelog M, Jeske SD, Asam C, Fuchs A, Wieser A, Gall C, Wytopil M, Mueller-Schmucker SM, Beileke S, Goekkaya M, Kling E, Geldmacher C, Rubio-Acero R, Plank M, Christa C, Willmann A, Vu M, Einhauser S, Weps M, Lampl BMJ, Almanzar G, Kousha K, Schwägerl V, Liebl B, Weber B, Drescher J, Scheidt J, Gefeller O, Messmann H, Protzer U, Liese J, Hoelscher M, Wagner R, Überla K, Steininger P; CoVaKo Study Group

Clinical and immunological benefits of full primary COVID-19 vaccination in individuals with SARS-CoV-2 breakthrough infections: A prospective cohort study in non-hospitalized adults